Project Grant R01CA308285
Award Date 7/13/26
Completion Date 6/30/31
Dollars Obligated $664K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- Grant Award Summary The National Cancer Institute awarded a Project Grant of $771,811 to the University of California, San Diego, effective June 1, 2026, through May 31, 2029, under the Cancer Treatment Research program (CFDA 93.395). The grant funds research to identify small molecule activators of Type I Interferon (IFN-I) signaling for cancer treatment. Specifically, the research team will discover small molecule inhibitors targeting USP18, a ubiquitin protease that suppresses the Type I...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a Project Grant of $770,666 to the University of Colorado's Office of Contracts and Grants (awarded March 19, 2026; completion February 28, 2028) to conduct fundamental research on splicing-mediated dysregulation of interferon signaling in cancer. The project investigates how transposon-derived exonization creates altered protein isoforms of the IFNAR2 gene that...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a $700,338 Project Grant on May 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research through April 30, 2031. This five-year award funds investigation into resistance mechanisms to asciminib, the first allosteric tyrosine kinase inhibitor (TKI) approved for treating chronic myeloid leukemia (CML). The research employs orthogonal...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $410,933 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on March 18, 2026, with completion anticipated by February 29, 2028. This exploratory research initiative (R21) focuses on developing next-generation small interfering RNA (siRNA) therapeutics to treat metastatic castration-resistant prostate cancer (mCRPC). The primary deliverable is the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $661,721 Project Grant to the University of California, San Diego for "Systematic Functional Mapping and Interrogation of Oncogenic Intrinsically Disordered Regions" under the Cancer Biology Research program (CFDA 93.396). The award, effective April 1, 2026 through March 31, 2031, supports fundamental cancer biology research aimed at identifying cancer cell vulnerabilities and drug resistance...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $648,626 to the University of California Irvine on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support a five-year project extending through March 31, 2031. This Project Grant funds fundamental research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically examining how PD-1 (Programmed Death-1) inhibition affects tumor...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $677,787 to The Regents of the University of California, San Francisco on August 26, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports a five-year research initiative (through July 31, 2030) investigating AIRE-expressing tumor-associated macrophages (AIRE+ TAMs) as novel mediators of tumor immune evasion. The research aims to characterize the molecular and...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a $668,362 Project Grant to The Regents of the University of California, San Francisco on July 7, 2026, with a completion date of June 30, 2031. This five-year award supports fundamental cancer biology research focused on decoding ribosomal RNA (rRNA) modifications and their role in cancer development and progression. The research will investigate how cancer cells...